Ciclopirox Therapeutic Cheat Sheet
Ciclopirox is the only hydroxypyridone antifungal agent with a unique mechanism of action differentiating it from other antimycotic agents. Unlike the azole-antifungals which block the sterol synthesis in the fungal cell membrane, ciclopirox functions by chelating cations resulting in the degradation of fungal cells, as well as proposed anti-inflammatory properties. It is available in a variety of …
Ciclopirox is the only hydroxypyridone antifungal agent with a unique mechanism of action differentiating it from other antimycotic agents. Unlike the azole-antifungals which block the sterol synthesis in the fungal cell membrane, ciclopirox functions by chelating cations resulting in the degradation of fungal cells, as well as proposed anti-inflammatory properties. It is available in a variety of … 
Generalized pustular psoriasis (GPP) is a rare, autoinflammatory condition, with acute, severe flares of diffuse sterile pustules and systemic symptoms that can be life-threatening. Historically, cyclosporine, methotrexate, retinoids, and biologics modulating the interleukin-17 (IL-17), IL-23, and tumor necrosis factor α pathways have been used off-label for management.1 Aberrant IL-36 signaling … 
Oxymetazoline is an adrenoreceptor agonist which is FDA-approved for dermatologic conditions including persistent facial erythema in rosacea and blepharoptosis. Functioning primarily as a vasoconstrictor with additional anti-inflammatory properties, oxymetazoline targets the sustained vasodilated state of cutaneous blood vessels in rosacea by inducing vasoconstriction and reducing the persistent f … 
Bimekizumab (Bimzelx®) is a new injectable medication FDA approved for plaque psoriasis. It is the first and only FDA approved IL-17A and IL-17F inhibitor for this disease, but is also being used as an off-label option for other conditions including psoriatic arthritis and hidradenitis suppurativa. This Therapeutic Cheat Sheet will focus on the on and off label uses of bimekizumab.
Bimekizuma … 
Current field-directed treatments of actinic keratosis (AK), a pre-malignant condition, are often limited by severe local reactions and/or complex treatment. Tirbanibulin, a novel potent anti-proliferative synthetic agent that inhibits tubulin polymerization and Src kinase signalling, offers a convenient, safe, and effective field treatment of actinic keratosis. We continue our surgical Therapeut … 